Integra LifeSciences (NASDAQ:IART) Shares Gap Down – Here’s Why

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s share price gapped down before the market opened on Wednesday. The stock had previously closed at $13.33, but opened at $12.77. Integra LifeSciences shares last traded at $13.27, with a volume of 71,069 shares traded.

Key Headlines Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Third-quarter adjusted EPS was $0.59, above the $0.56 consensus and up from $0.54 a year earlier. GAAP EPS improved to $0.19 from a $0.07 loss, while operating cash flow rose to $96 million. Integra LifeSciences surpasses Q3 earnings estimates
• Positive Sentiment: Specialty Surgery remained a growth driver. Segment revenue increased 3.9% year over year, with organic Neurosurgery sales up 6.5%, helping offset weakness elsewhere. Integra also reduced its leverage ratio to 3.8x and reported $1.5 billion in net debt. Integra third-quarter 2026 financial results
• Positive Sentiment: Debt refinancing reduces near-term refinancing risk. Integra completed a $2.1 billion refinancing that extends maturities and increases covenant flexibility. The transaction is intended to support liquidity and continued deleveraging. Integra refinancing transactions
• Neutral Sentiment: Full-year guidance was reaffirmed. Integra maintained 2026 revenue guidance of $1.634 billion to $1.654 billion and adjusted EPS guidance of $2.30 to $2.40. Fourth-quarter revenue is expected to range from $413 million to $433 million, with adjusted EPS of $0.61 to $0.71.
• Negative Sentiment: Revenue fell short of estimates and growth was limited. Third-quarter revenue increased 2.3% to $411.2 million, below the $413.2 million analyst estimate. The company expects fourth-quarter reported revenue to decline between 0.5% and 5.2% year over year. Integra Q3 key metrics versus estimates
• Negative Sentiment: Flood damage and segment weakness remain concerns. Cincinnati facility flooding reduced quarterly revenue by approximately $7 million, while Tissue Reconstruction revenue declined 2.2%. The refinancing is also expected to increase interest costs by near the high end of the previously indicated 100-to-200-basis-point range.
• Negative Sentiment: Analyst sentiment weakened. Truist lowered its price target for IART to $15 from $19, adding pressure to the stock’s outlook. Truist cuts Integra price target

Analyst Upgrades and Downgrades

IART has been the topic of several research analyst reports. Citigroup reaffirmed a “neutral” rating and issued a $15.00 price objective (down from $19.00) on shares of Integra LifeSciences in a research note on Monday, October 5th. UBS Group initiated coverage on Integra LifeSciences in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 target price on the stock. Weiss Ratings downgraded Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. BMO Capital Markets lowered their target price on Integra LifeSciences from $18.00 to $15.00 and set a “market perform” rating for the company in a research note on Monday, October 5th. Finally, Truist Financial dropped their target price on shares of Integra LifeSciences from $19.00 to $15.00 and set a “hold” rating for the company in a report on Wednesday, October 14th. One equities research analyst has rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $16.71.

Integra LifeSciences Price Performance

The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11. The stock has a market cap of $959.72 million, a price-to-earnings ratio of -138.21, a price-to-earnings-growth ratio of 0.71 and a beta of 1.21. The business’s 50-day simple moving average is $15.67 and its two-hundred day simple moving average is $15.55.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.03. The firm had revenue of $411.18 million for the quarter, compared to analysts’ expectations of $413.16 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. During the same quarter in the previous year, the firm posted ($0.07) earnings per share. Research analysts expect that Integra LifeSciences Holdings Corporation will post 2.39 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Sequoia Financial Advisors LLC increased its holdings in Integra LifeSciences by 221.7% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 45,785 shares of the life sciences company’s stock worth $822,000 after purchasing an additional 31,552 shares in the last quarter. WINTON GROUP Ltd bought a new position in Integra LifeSciences in the second quarter valued at about $1,843,000. Integrated Wealth Concepts LLC bought a new position in Integra LifeSciences in the second quarter valued at about $84,000. Corient Private Wealth LP boosted its stake in shares of Integra LifeSciences by 66.9% during the second quarter. Corient Private Wealth LP now owns 22,749 shares of the life sciences company’s stock valued at $409,000 after purchasing an additional 9,120 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of Integra LifeSciences by 12.4% during the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock valued at $26,241,000 after purchasing an additional 160,814 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.